Skip to main content

Bausch Health Companies Inc. Value Stock - Dividend - Research Selection

Bausch health

ISIN: CA0717341071 , WKN: A2JQ1X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Tracking John Paulson's Paulson & Company Portfolio - Q4 2025 Update

2026-03-24
John Paulson’s Q4 2025 13F: $3.26B, 9-stock portfolio led by Madrigal Pharma (MDGL).

Should Bausch Health’s Profit Return and 2026 Outlook Shift the Investment Case for BHC?

2026-02-27
Bausch Health Companies recently reported fourth-quarter 2025 revenue of US$2,796 million and a net loss of US$112 million, alongside full-year 2025 revenue of US$10.27 billion and net income of US$157 million, while also recording a US$145 million goodwill impairment and issuing 2026 revenue guidance of US$10.63–US$10.88 billion. Against this backdrop, Bausch and its OraPharma dental unit marked the 25th anniversary of ARESTIN®, the only FDA-approved locally applied antibiotic adjunct for...

Barclays Maintains Equal-Weight on Bausch Health Companies, Lowers Price Target to $7

2026-02-25
Barclays analyst Glen Santangelo maintains Bausch Health Companies (NYSE:BHC) with a Equal-Weight and lowers the price target from $8 to $7.

Oruka Therapeutics: A Potential Future Psoriasis Play

2026-02-25

OTC Artificial Tears Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

2026-02-24
The OTC Artificial Tears market is projected to expand from USD 4.93 billion in 2025 to USD 7.22 billion by 2033, growing at a CAGR of 4.88%. This growth is driven by increased accessibility in public spaces, rising dry eye syndrome cases due to aging and digital exposure, and heightened awareness of eye health. Artificial tears mimic natural tears to relieve dry eyes, making them integral to eye care routines. Key players, including AbbVie, Akorn, Alcon, Bausch Health, and Johnson & Johnson, ar

Vision Care Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

2026-02-24
The Vision Care market is expected to grow from US$81.23 billion in 2025 to US$117.75 billion by 2033, at a CAGR of 4.75%. Factors driving this growth include enhanced access to healthcare, increased awareness of eye health, and innovations in contact lenses, eyeglass frames, and lens materials. The demand for vision care is soaring globally due to rising digital eye strain and age-related conditions, while healthcare initiatives highlight the importance of regular check-ups. Leading companies l

Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook

2026-02-23
Bausch Health Companies Inc. (NYSE:BHC) is among the 7 Oversold Pharma Stocks to Buy Now. Bausch Health Companies Inc. (NYSE:BHC) is one of the most oversold stocks. TheFly reported on February 19 that Bank of America raised its price target for Bausch + Lomb (BLCO) to $15 from $13 and kept an Underperform rating. The […]

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

2026-02-23
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada. With this approval, Canadian physicians are able to offer one of the most advanced dual-wave

Bausch Health Weighs China Aesthetics Push Against ARESTIN Milestone And Debt

2026-02-22
Bausch Health Companies (NYSE:BHC) agreed to acquire Shibo's aesthetics distribution business in China, expanding its presence in that market. The company marked the 25th anniversary of its ARESTIN® product, highlighting its long-running role in the portfolio. ARESTIN® has been introduced into additional markets, including Canada and Puerto Rico, alongside adjustments to Bausch Health's capital structure. Bausch Health Companies, listed as NYSE:BHC, operates across eye health,...

Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?

2026-02-20
IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.